Fresenius SE & Co. KGaA (FSNUY)
| Market Cap | 27.39B |
| Revenue (ttm) | 23.92B |
| Net Income (ttm) | 456.12M |
| Shares Out | 563.24M |
| EPS (ttm) | 0.81 |
| PE Ratio | 60.05 |
| Forward PE | 12.72 |
| Dividend | n/a |
| Ex-Dividend Date | May 27, 2025 |
| Volume | 3,073 |
| Average Volume | 81,499 |
| Open | 12.12 |
| Previous Close | 12.10 |
| Day's Range | 12.12 - 12.22 |
| 52-Week Range | 7.43 - 12.44 |
| Beta | 0.96 |
| RSI | 67.79 |
| Earnings Date | May 7, 2025 |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; e... [Read more]
News
Fresenius medical care outlines 2025 operating income growth targets amid strategic transformations
Fresenius SE & Co. KGaA 2025 Q1 - Results - Earnings Call Presentation
Fresenius SE & Co. KGaA (FSNUF) Q1 2025 Earnings Call Transcript
Fresenius SE & Co. KGaA reports Q1 results
Fresenius posts profit beat in first quarter, confirms outlook
German healthcare group Fresenius beat analysts' adjusted operating profit expectations for the first quarter on Wednesday, citing a strong performance at its drug making division Kabi.
Fresenius: Holding On For Longer-Term Growth Driven By Demand In Kidney Care Segment
Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps
Pacira BioSciences, Inc . (NASDAQ: PCRX) on Monday settled its litigations with Fresenius Kabi USA , Jiangsu Hengrui Pharmaceuticals Co ., Ltd., and eVenus Pharmaceuticals Laboratories, Inc . related...
Pacira surges on patent settlement with Fresenius
Fresenius gets FDA approval for biosimilars of Amgen's bone-condition drugs
Fresenius: Turnaround For Company, Stock Price
Fresenius SE's restructuring and dividend reinstatement signal strong growth. Read why FSNUF stock may not be a long-term buy despite short-term gains.
Health Care Roundup: Market Talk
Find insight on Bayer, Sandoz, Fresenius and more in the latest Market Talks covering Health Care.
Fresenius SE & Co KGaA (FSNUF) Full Year 2024 Earnings Call Highlights: Strong Growth and ...
Fresenius SE & Co KGaA (FSNUF) Full Year 2024 Earnings Call Highlights: Strong Growth and Strategic Advancements
Fresenius SE & Co. KGaA 2024 Q4 - Results - Earnings Call Presentation
Fresenius SE & Co. KGaA (FSNUF) Full Year and Q4 2024 Earnings Call Transcript
Germany has homework to do, Fresenius CEO says
Fresenius CEO Michael Sen discusses the company's latest financial results and the state of the German economy.
Fresenius SE & Co. KGaA GAAP EPS of €0.69, revenue of €5.5B; initiates outlook for FY 2025
Fresenius Shares Jump After Higher Profit, Dividend Payout
Fresenius Sees Hospital Costs Holding Back Higher Profit in 2025
Fresenius SE expects profit growth to slow in 2025 as cost pressures in its hospital business rise, partly due to the expiration of government funding.
Fresenius targets high teens to high 20s operating income growth for 2025 amid transformation progress
It's clear the old world order has come to an end, says Fresenius CEO
Michael Sen, CEO of Fresenius, discusses geopolitics and the healthcare industry.
Fresenius: The Signs Of A Significant Turnaround Are Getting Clearer And Clearer
Fresenius is showing significant upside, with a 25% RoR since early 2024, driven by strong earnings growth and strategic execution. The company's turnaround is evident with improved EPS, reduced lever...
Siemens Taps Ex-Nestle CEO Schneider for Board, Potential Chair
Siemens AG is proposing that Mark Schneider, former chief executive officer of Nestle SA and Fresenius SE, join its supervisory board with the plan of later becoming chairman.
DaVita: Better Results Than Fresenius, But A 'Hold' Due To Valuation
Fresenius SE & Co. KGaA (FSNUF) Q3 2024 Earnings Call Transcript
Fresenius SE Raises Guidance After Strong Kabi, Helios Performances
The healthcare company lifted its full-year guidance after a robust third quarter driven by Kabi and good organic growth at Helios.